Navigation Links
GelFix(TM) Posterior Spinal Distraction Implant Receives CE Mark
Date:3/8/2010

CRANBURY, N.J., March 8 /PRNewswire/ -- Replication Medical, Inc., a developer of proprietary, hydrogel based products for the spine and other surgical applications, announced today that it has received a CE mark for its GelFix Posterior Spinal Distraction implant.    A CE mark is the quality assurance certification requirement recognized by members of the European Union for sales into those countries.

The GelFix device is a one-piece posterior spinal implant made from HPAN, a biocompatible hydrogel which exhibits desirable mechanical properties including compressive resistance with a dynamic response.  The GelFix distraction implant is used as a spacer between the spinous processes to provide separation and prevent nerve pinching.  The product is available in three sizes to fit the typical range of spinal stenosis patients.

The CE mark for this implant follows the approval the company received last year from the Food and Drug Administration (FDA) to market its EnGuard™ Vessel Guard.  The EnGuard device is indicated for use as a protective cover for blood vessels following anterior spine surgery and is composed of the same biocompatible polymer.

The EnGuard Vessel Guard is the first in a series of innovative products based on their proprietary hydrogel technology that the company is launching this year in the United States.

Commenting on these developments, Ann Prewett, President and CEO, said, "The GelFix implant provides a unique, minimally invasive solution for treating spinal stenosis, a leading cause of back pain."   The GelFix device acts as a dynamic spacer, compressing under load yet maintaining separation of the interspinous space.  In this manner, some of the complications associated with rigid spacers such as breakage of the bones of the spinous process or subsidence may be avoided.    

"Our products provide a technologically advanced alternative to the conventional metal and hard plastic implants which have dominated orthopedics and spine to date.   Replication Medical looks forward to entering these markets because we offer the only technology which provides a biomimetic solution to treat these medical conditions," she explained.

The GelFix interspinous implant may not only reduce pain, but also increase the mobility of the patient.   "The key to the procedure is the minimally invasive technique which can be used to implant the device.  We insert the implant between the appropriate spinous processes and in 8-10 hours, the implant increases in size and gives us the stability that we need," said Carl Lauryssen, M.D., one of Replication Medical's surgeon advisors.

The GelFix Posterior Spinal Distraction Implant is not currently approved for sale or distribution in the United States.

ABOUT REPLICATION MEDICAL

Replication Medical, Inc. is a developer of proprietary, hydrogel based products for the spinal market and other surgical applications.   Headquartered in Cranbury, New Jersey, the Company is a leader in the design and development of novel biometic hydrogel implants.  

SOURCE Replication Medical, Inc.

Back to top
'/>"/>
SOURCE Replication Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Alseres Pharmaceuticals Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
2. Mayo Clinic Clarifies Diagnosis and Treatment for Rare, Serious Blood Vessel Disease of Brain and Spinal Cord
3. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
4. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
5. Genzyme Genetics Announces Launch of Carrier Testing and Prenatal Diagnosis for Spinal Muscular Atrophy
6. CoreSpine Technologies Expands Spinal Disc Site Preparation Efforts
7. Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
8. Synapse Biomedical Receives FDA Approval of NeuRx Diaphragm Pacing System (DPS)(TM) For Spinal Cord Injury Breathing Applications
9. New Minimally Invasive Surgical Procedure Restores Quality of Life in Patients With Potentially Debilitating Spinal Condition
10. Markers in Blood and Spinal Fluid, and a New Imaging Agent, Show Promise for Early Detection of Alzheimers
11. Neuralstem Licenses Cleveland Clinic Spinal Cord Injection Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Ill. , June 23, 2016  In a startling report ... are failing their residents by lacking a comprehensive, proven plan to ... a definitive ranking of how states are tackling the worst ... to only four states – Kentucky , ... Vermont . Of the 28 failing states, three ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... Forecast to 2022" report to their offering. ... date financial data derived from varied research sources to present ... impact on the market during the next five years, including ... sub markets, regional and country level analysis. The report provides ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... ... policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at ... on several important health care topics including advance care planning, healthcare costs and ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from PsychTests.com reveals that behind the tendency to set ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA ... the Road To Recovery® program to drive cancer patients to and from their cancer ... ensure the highest quality of life and ongoing independence. Getting to and from ...
Breaking Medicine News(10 mins):